MAPK8 and cardiac hypertrophy: In line with the above findings, our data demonstrated that delphinidin markedly inhibited the activation of ERK1/2, p38 and JNK1/2 in vivo and in vitro, suggesting that delphinidin inhibits cardiac hypertrophy by blocking ROS-dependent MAPK signaling.